Breaking News Instant updates and real-time market news.

PRQR

ProQR Therapeutics

$5.96

-0.19 (-3.09%)

07:15
10/09/19
10/09
07:15
10/09/19
07:15

ProQR shares could more than double on tomorrow's data, says Cantor Fitzgerald

Cantor Fitzgerald analyst Eliana Merle reiterates an Overweight rating on ProQR Therapeutics with a $40 price target ahead of tomorrow's data update on lead program QR-110, which is in development for LCA10, a rare genetic form of blindness. Investors view ProQR and QR-110 as a "show-me story," but these data could lift a "significant overhang" around platform safety and serve as a "key piece of clinical de-risking" for QR-110's Phase 2/3 trial under way, Merle tells investors in a research note partially titled "A double by this time tomorrow?". The analyst thinks the stock could trade up 50%-150% tomorrow versus downside to its cash position of ~$2 per share, or ~65%.

  • 11

    Oct

PRQR ProQR Therapeutics
$5.96

-0.19 (-3.09%)

12/19/18
RBCM
12/19/18
INITIATION
Target $29
RBCM
Outperform
ProQR Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated ProQR Therapeutics with an Outperform rating and a price $29. The analyst believes that the company's recent QR-110 data serves to de-risk its ophthalmology portfolio, offering "upside potential from pipeline expansion in 2019" and beyond. MacKay is also positive on ProQR Therapeutics position of having an "established proof of concept utilizing RNA-based therapies to target rare diseases uniquely sheltered from safety and efficacy challenges" faced by its therapeutic class.
01/14/19
CANT
01/14/19
NO CHANGE
CANT
Cantor highlights BioMarin, ProQR after JPMorgan Healthcare Conference
Cantor Fitzgerald analyst Eliana Merle found BioMarin's (BMRN) gene therapy platform advances and "improved risk-reward" for ProQR Therapeutics' (PRQR) USH2A program ahead of key data mid-2019 as most notable from the JPMorgan Healthcare Conference. The analyst left feeling more confident about BioMarin's gene therapy platform, which she thinks could positively surprise over the next 12-24 months as new programs enter the clinic. Further, she thinks the safety events in question at this point are likely overdone in ProQR shares following the 15% selloff since the conference. Merle now sees an "even more" favorable risk/reward into the company's mid-2019 proof-of-concept readout from a separate program.
02/20/19
SBSH
02/20/19
NO CHANGE
SBSH
Buy
Citi opens 90-day catalyst watch on ProQR Therapeutics
Citi analyst Yigal Nochomovitz opened a 90-day catalyst watch on ProQR Therapeutics in anticipation of the interim Phase 1/2 Wings data for QR-313 in dystrophic epidermolysis bullosa. On positive data, or evidence of exon skipping in biopsies and evidence of skin lesion/blister resolution, the analyst sees the stock up 15%-25%. On negative data, he sees downside of 10%-15%. Nochomovitz has a Buy rating on ProQR Therapeutics.
03/27/19
CANT
03/27/19
NO CHANGE
Target $40
CANT
Overweight
ProQR Therapeutics spin-out 'smart, but not surprising,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle thinks ProQR Therapeutics' spin-out of its dystrophic epidermolysis bullosa program is a "smart, but not surprising," strategic move. Given that the company has communicated it wants to focus on its ophthalmology programs, investors are unlikely to find this announcement about the skin program spin-out surprising, Merle tells investors in a research note. The analyst keeps an Overweight rating on ProQR Therapeutics with a $40 price target.

TODAY'S FREE FLY STORIES

SAVE

Spirit Airlines

$37.33

0.08 (0.21%)

, EADSY

Airbus

$0.00

(0.00%)

11:33
10/23/19
10/23
11:33
10/23/19
11:33
Periodicals
Spirit Airlines near deal for as many as 100 Airbus A320 jets, Reuters says »

Spirit Airlines (SAVE) is…

SAVE

Spirit Airlines

$37.33

0.08 (0.21%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 13

    Nov

KAMN

Kaman

$58.38

-0.2 (-0.34%)

11:33
10/23/19
10/23
11:33
10/23/19
11:33
Hot Stocks
Kaman executes long term agreement with Winglet Technology »

Kaman Composites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

TWTR

Twitter

$38.93

0.11 (0.28%)

11:32
10/23/19
10/23
11:32
10/23/19
11:32
Earnings
Fly Intel: What to watch in Twitter earnings report »

Twitter (TWTR) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

ABMD

Abiomed

$175.20

4.45 (2.61%)

, ABT

Abbott

$81.49

0.95 (1.18%)

11:29
10/23/19
10/23
11:29
10/23/19
11:29
Recommendations
Trial for potential Abiomed competition pushed back a year, says Piper Jaffray »

This morning, the primary…

ABMD

Abiomed

$175.20

4.45 (2.61%)

ABT

Abbott

$81.49

0.95 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 13

    Nov

HEMA

HemaCare Corp.

$0.00

(0.00%)

11:27
10/23/19
10/23
11:27
10/23/19
11:27
Periodicals
Breaking Periodicals news story on HemaCare Corp. »

HemaCare Corp. working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$175.20

4.45 (2.61%)

, ABT

Abbott

$81.52

0.98 (1.22%)

11:27
10/23/19
10/23
11:27
10/23/19
11:27
Hot Stocks
Abiomed jumps after Abbott heart pump trial pushed back one year »

An update today on…

ABMD

Abiomed

$175.20

4.45 (2.61%)

ABT

Abbott

$81.52

0.98 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 13

    Nov

MGNX

MacroGenics

$9.87

-1.17 (-10.60%)

, ZYME

Zymeworks

$30.25

-0.26 (-0.85%)

11:26
10/23/19
10/23
11:26
10/23/19
11:26
Recommendations
MacroGenics, Zymeworks analyst commentary  »

MacroGenics price target…

MGNX

MacroGenics

$9.87

-1.17 (-10.60%)

ZYME

Zymeworks

$30.25

-0.26 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 06

    Nov

TRU

TransUnion

$82.71

2.31 (2.87%)

11:26
10/23/19
10/23
11:26
10/23/19
11:26
Conference/Events
TransUnion management to meet with SunTrust »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 19

    Nov

CVM

CEL-SCI

$7.35

(0.00%)

11:25
10/23/19
10/23
11:25
10/23/19
11:25
Options
Cel Sci call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCG

NRC Group

$13.00

(0.00%)

, ECOL

US Ecology

$66.75

0.245 (0.37%)

11:25
10/23/19
10/23
11:25
10/23/19
11:25
Conference/Events
US Ecology to host special shareholder meeting »

Special Shareholder…

NRCG

NRC Group

$13.00

(0.00%)

ECOL

US Ecology

$66.75

0.245 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 31

    Oct

SNAP

Snap

$13.24

-0.76 (-5.43%)

11:19
10/23/19
10/23
11:19
10/23/19
11:19
Hot Stocks
Snap says DOJ, SEC no longer pursuing investigations of IPO disclosures »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/23/19
10/23
11:17
10/23/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
10/23/19
10/23
11:16
10/23/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$184.34

2.07 (1.14%)

11:05
10/23/19
10/23
11:05
10/23/19
11:05
Hot Stocks
Facebook shares up 1.6% as CEO testifies on Capitol Hill »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

CNC

Centene

$48.49

-0.28 (-0.57%)

11:05
10/23/19
10/23
11:05
10/23/19
11:05
Options
Centene call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

D

Dominion

$83.07

0.29 (0.35%)

11:03
10/23/19
10/23
11:03
10/23/19
11:03
Hot Stocks
Dominion, Smithfield Foods double investment in renewable natural gas to $500M »

Dominion Energy and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

BA

Boeing

$345.52

8.07 (2.39%)

11:02
10/23/19
10/23
11:02
10/23/19
11:02
Hot Stocks
Boeing CFO says it will take 'several quarters' to deliver parked 737 MAX jets »

CFO Greg Smith says it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BA

Boeing

$345.79

8.34 (2.47%)

11:00
10/23/19
10/23
11:00
10/23/19
11:00
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing says studying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

MMM

3M

$166.93

-0.63 (-0.38%)

10:55
10/23/19
10/23
10:55
10/23/19
10:55
Options
3M put volume heavy and directionally bearish »

Bearish flow noted in 3M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GLOG

GasLog

$14.29

0.325 (2.33%)

, GLOP

GasLog Partners

$20.24

0.35 (1.76%)

10:55
10/23/19
10/23
10:55
10/23/19
10:55
Conference/Events
Deutsche Bank shipping analyst to hold analyst/industry conference call »

Analysts, along with…

GLOG

GasLog

$14.29

0.325 (2.33%)

GLOP

GasLog Partners

$20.24

0.35 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 30

    Oct

  • 06

    Nov

BA

Boeing

$346.26

8.81 (2.61%)

10:54
10/23/19
10/23
10:54
10/23/19
10:54
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BA

Boeing

$346.90

9.45 (2.80%)

10:53
10/23/19
10/23
10:53
10/23/19
10:53
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing sees first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FCX

Freeport McMoRan

$9.98

0.06 (0.60%)

10:51
10/23/19
10/23
10:51
10/23/19
10:51
Hot Stocks
Freeport McMoRan says current copper prices not sustainable »

Management said the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BA

Boeing

$347.23

9.78 (2.90%)

10:50
10/23/19
10/23
10:50
10/23/19
10:50
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing: US-China trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

UXIN

Uxin

$2.68

-0.04 (-1.47%)

10:47
10/23/19
10/23
10:47
10/23/19
10:47
Downgrade
Uxin rating change  »

JPMorgan downgrades Uxin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.